GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » OraSure Technologies Inc (NAS:OSUR) » Definitions » Equity-to-Asset

OraSure Technologies (OraSure Technologies) Equity-to-Asset : 0.89 (As of Dec. 2023)


View and export this data going back to 1992. Start your Free Trial

What is OraSure Technologies Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. OraSure Technologies's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $430.7 Mil. OraSure Technologies's Total Assets for the quarter that ended in Dec. 2023 was $482.8 Mil. Therefore, OraSure Technologies's Equity to Asset Ratio for the quarter that ended in Dec. 2023 was 0.89.

The historical rank and industry rank for OraSure Technologies's Equity-to-Asset or its related term are showing as below:

OSUR' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.82   Med: 0.87   Max: 0.9
Current: 0.89

During the past 13 years, the highest Equity to Asset Ratio of OraSure Technologies was 0.90. The lowest was 0.82. And the median was 0.87.

OSUR's Equity-to-Asset is ranked better than
88.74% of 870 companies
in the Medical Devices & Instruments industry
Industry Median: 0.65 vs OSUR: 0.89

OraSure Technologies Equity-to-Asset Historical Data

The historical data trend for OraSure Technologies's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OraSure Technologies Equity-to-Asset Chart

OraSure Technologies Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.88 0.88 0.83 0.82 0.89

OraSure Technologies Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.82 0.86 0.87 0.88 0.89

Competitive Comparison of OraSure Technologies's Equity-to-Asset

For the Medical Instruments & Supplies subindustry, OraSure Technologies's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


OraSure Technologies's Equity-to-Asset Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, OraSure Technologies's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where OraSure Technologies's Equity-to-Asset falls into.



OraSure Technologies Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

OraSure Technologies's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=430.671/482.845
=0.89

OraSure Technologies's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )=Total Stockholders Equity/Total Assets
=430.671/482.845
=0.89

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


OraSure Technologies  (NAS:OSUR) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


OraSure Technologies Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of OraSure Technologies's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


OraSure Technologies (OraSure Technologies) Business Description

Traded in Other Exchanges
Address
220 East First Street, Bethlehem, PA, USA, 18015
OraSure Technologies is a medical devices company that develops, manufactures, and distributes oral fluid diagnostic and collection devices. Its reportable segments are diagnostics and molecular solutions. The diagnostics segment produces rapid oral diagnostic tests and specimen collection devices for infectious diseases such as HIV and HCV. The molecular solutions segment specializes in kits used to collect, stabilize, and transport genetic material samples for molecular testing of both hereditary diseases and infectious diseases, such as COVID-19. The company gets most of its sales from the molecular solutions business, derived mainly from customers in the United States.
Executives
Kathleen Gallagher Weber officer: Chief Product Officer 220 EAST FIRST STREET, BETHLEHEM PA 18017
Michele Marie Miller officer: VP, Finance and Controller 220 EAST FIRST STREET, BETHLEHEM PA 18017
Robert W. Mcmahon director 250 CAMPUS DRIVE, MARLBOROUGH MA 01752
Kenneth J Mcgrath officer: Chief Financial Officer C/O ORASURE TECHNOLOGIES, INC., 220 E. FIRST STREET, BETHLEHEM PA 18015
Ronny B Lancaster director ORASURE TECHNOLOGIES INC, 220 EAST FIRST STREET, BETHLEHEM PA 18015
Mara G. Aspinall director 7381 NORTH MOON SPIRIT LANE, TUCSON AZ 85718
Nancy J Gagliano director 33 GRANITE WAY, GRANTHAM NH 03753
Michael Celano director 220 EAST FIRST STREET, BETHLEHEM PA 18015
Manner Carrie Eglinton director, officer: President & CEO C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094
Scott Gleason officer: Interim CFO/SVP IR 1809 SOUTH 2500 EAST, SALT LAKE CITY UT 84108
Eamonn P Hobbs director C/O DELCATH SYSTEMS, INC., 600 FIFTH AVENUE, NEW YORK NY 10020
Anne Clem Whitaker director 109 BRIERY BRANCH COURT, MORRISVILLE NC 27560
James A Datin director 21 ESTATES DRIVE, DOYLESTOWN PA 18901
Lelio Marmora director 64 RUE DE VESENEX, DIVONNE LES BAINS I0 01220
Lisa Nibauer officer: President of Diagnostics 1 CRESENT PLACE, SHORT HILLS NJ 07078